Fig. 1 · Structure

Documents & Downloads

Fenticonazole nitrate

Cat. No. A11852 CAS 73151-29-8
Fenticonazole nitrate is an azole antifungal agent.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Fenticonazole nitrate Research Summary

This section summarizes 1 in vitro study of Fenticonazole nitrate from 1 published reference. In vitro models include cos-7 cells.

Fenticonazole nitrate In Vitro Studies

Fenticonazole was evaluated in transfected cos-7 cells using luciferase activity normalized to renilla activity. Compared with DMSO, Fenticonazole exhibited weak PPARγ agonistic activity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Fenticonazole activity in transfected cells

Cell-based study · cos-7 cells [1]

Transfected cos-7 cells were treated with Fenticonazole, with DMSO as the negative control. Fenticonazole exhibited weak PPARγ agonistic activity compared with DMSO, assessed using luciferase activity normalized to renilla activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The luciferase activity was normalized to renilla activity.Reported result At a concentration of 30 or 100 μM for another 24 h: podophyllotoxone exhibited weak PPARγ agonistic activity, similar to fenticonazole (FN).[1]

Literature-Reported Treatment Conditions

Treatment concentration
30 or 100 μM
Exposure duration
After 24 h of incubation, the transfected cells were treated with DMSO, podophyllotoxone, FN and Rosi at a concentration of 30 or 100 μM for another 24 h.
Method
the transfected cells were treated
Co-treatment
Other interventions in this design: hPPARγ; PPRE × 3 TK-luciferase plasmids; renilla luciferase plasmids. Compound effect isolated by the comparison: compared with DMSO group.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Fenticonazole

The paper names Fenticonazole without stating the salt or form; not verified as the nitrate form supplied as A11852. No dose conversion or lot validation.

2. Results > 2.5. TR-FRET Competitive Binding Assay and PPARγ Transactivation Assay (S91); 3. Materials and Methods > 3.5. Materials (S128); 3. Materials and Methods > 3.7. PPARγ Transactivation Assay (S142, S143, S145, S146, S147); Figure 4 legend (S156)

The luciferase activity was normalized to renilla activity.: The luciferase activity was normalized to renilla activity.; comparator: DMSO serving as the negative control and rosiglitazone (Rosi) serving as the positive control — 2. Results > 2.5. TR-FRET Competitive Binding Assay and PPARγ Transactivation Assay (S91); 3. Materials and Methods > 3.7. PPARγ Transactivation Assay (S143, S146)

Specifications

Manufacturer Adooq Bioscience
CAS Number 73151-29-8
Formula C24H20Cl2N2OS.HNO3
Molecular Weight 518.41
SMILES
C1=CC=C(C=C1)SC2=CC=C(C=C2)COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl.[N+](=O)(O)[O-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 103 mg/mL (198.68 mM)
Water Insoluble
Ethanol 2 mg/mL (3.85 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Fenticonazole nitrate Research References

  1. [1] Lian YE, Wang M, Ma L, et al. Identification of Novel PPARγ Partial Agonists Based on Virtual Screening Strategy: In Silico and In Vitro Experimental Validation. Molecules (2024). PMID: 39459249 DOI: 10.3390/molecules29204881 Source material

Added to your cart

View Cart Checkout
Loading...